Why Is Liver Cancer Treatment Different for Patients with Cirrhosis? (2026 Update)

For patients with cirrhosis, liver cancer treatment depends not only on tumor size and number but also on liver function grade (Child-Pugh) and portal pressure — meaning that even tumors of the same size may call for very different treatment options.

Key Takeaways

• Liver cancer usually develops on top of chronic hepatitis or cirrhosis, so staging alone isn't enough — liver function grade (Child-Pugh) and portal pressure also drive treatment decisions.
• Korea's 5-year relative survival rate for liver cancer is 40.4% (National Cancer Registration Statistics 2019–2023, Central Cancer Registry, National Cancer Center Korea). This is a nationwide figure for Korea, not from any single hospital.
• When liver function is good and the tumor is small, resection or transplant is considered first; when liver function is reduced, lower-burden options such as radiofrequency ablation (RFA) or embolization are prioritized.
• When liver function is severely impaired, systemic chemotherapy can actually worsen liver damage, so the focus shifts to symptom control, preserving liver function, and evaluating transplant eligibility.
• For patients with chronic hepatitis B or C, antiviral therapy and liver function testing continue for life, uninterrupted before and after liver cancer treatment.

Why does cirrhosis narrow treatment options?

• A cirrhotic liver is already fibrotic, so it has less capacity to tolerate the stress of surgery or medication compared to a healthy liver.
• Even with tumors of the same size and number, the recommended treatment can differ completely depending on liver function, portal pressure, and hepatitis status. In liver cancer, treatment isn't decided by TNM stage alone — staging systems that combine tumor status, liver function (Child-Pugh), and overall performance status (such as BCLC) are widely used instead.
• Liver function grade is determined by combining bilirubin, albumin, coagulation values, and the presence of ascites or jaundice, and this grade becomes the key criterion for whether a patient can withstand surgery or safely undergo a procedure like embolization.
• That's why submitting recent liver function test results alongside imaging (contrast-enhanced CT or MRI) is essential for an accurate remote review (pre-arrival review).

What treatments are considered at each stage of cirrhosis?

• In the very early and early stages — small, few tumors with good liver function — liver resection is the first choice, and if the tumor location allows, laparoscopic or robotic resection is used to speed recovery.
• When resection is difficult but the tumor is small and limited in number, radiofrequency ablation (RFA) is used to burn away the tumor; when liver function is significantly reduced but tumor size and number fall within set criteria, liver transplantation becomes the definitive treatment.
• In the intermediate stage, with multiple tumors scattered through the liver, transarterial chemoembolization (TACE) is the mainstay, sometimes combined with radioembolization, stereotactic body radiation therapy (SBRT), or particle therapy.
• In the advanced stage — vascular invasion or spread beyond the liver — systemic drug therapy is central, with combinations of immune checkpoint inhibitors and anti-angiogenic agents now the standard first-line approach.
• When liver function is severely impaired, chemotherapy can cause further liver damage, so treatment centers on symptom control, preserving liver function, and evaluating transplant candidacy.

What is the order of tests and treatment?

• Step 1, Diagnosis — in patients with cirrhosis or chronic hepatitis, diagnosis is based on the characteristic blood flow pattern on contrast-enhanced CT or MRI plus tumor markers such as AFP; in many cases a biopsy isn't even needed.
• Step 2, Staging and liver function assessment — the number and size of tumors, vascular invasion, Child-Pugh grade, and overall performance status are evaluated together to determine the treatment stage (very early to terminal).
• Step 3, Treatment planning — hepatobiliary-pancreatic surgery, gastroenterology, radiation oncology, and radiology work as one team to decide which stage calls for which treatment; often treatment doesn't end with a single approach but proceeds through a sequence of methods.
• Step 4, Treatment — resection, RFA, embolization, radiation therapy, particle therapy, transplantation, or drug therapy is chosen according to what the liver can tolerate.
• Step 5, Follow-up — for the first 1–2 years after treatment, contrast-enhanced CT/MRI and AFP are repeated every few months, and for patients with chronic hepatitis B or C, antiviral therapy and liver function testing continue for life.

FAQ — Can a foreign patient with cirrhosis-related liver cancer receive a liver transplant?

It can be considered if tumor size and number fall within accepted criteria and there is no spread beyond the liver. However, a donor must be a family member, review under Korean law is required, and because deceased-donor organs are prioritized for domestic wait-listed patients, foreign patients are evaluated on the premise of a living-donor transplant. Eligibility and required documents are explained at the remote review (pre-arrival review) stage.

FAQ — I was told my liver function is too poor for surgery. Are there other options?

Whether liver function can tolerate resection is assessed by the same standards everywhere in the world. That said, other paths may remain open — RFA, embolization, radiation therapy, or transplantation — so if you send your liver function values (bilirubin, albumin, coagulation markers) along with your imaging, we can outline the alternatives available to you.

FAQ — Do I need to keep taking hepatitis B medication during liver cancer treatment?

Yes. Antiviral medication should be continued without interruption, both before and after liver cancer treatment. Because liver cancer can recur in a different part of the liver beyond the treated area, follow-up intervals tend to be tighter than for other cancers, and arrangements can be made so you can return home with a prescription issued in Korea.

Sources and Notes

• This article was written based on general information on liver cancer from the National Cancer Registration Statistics 2019–2023 (Central Cancer Registry, National Cancer Center Korea), SEER (U.S. National Cancer Institute), the National Cancer Information Center, and NCCN patient guideline-level resources.
• This content is intended for general medical information purposes only; actual diagnosis, treatment methods, and outcomes may vary by individual condition. Please consult with a medical professional to determine an accurate diagnosis and treatment plan.